Previously treated with an HCV regimen containing an NS5A inhibitor Chronic hepatitis C genotype 5

Previous NS5A inhibitor therapy for chronic hepatitis C genotype 5 (HCVGT5) is associated with a higher risk of relapse than genotype 1 treatment. However, the efficacy and effectiveness of treatment with direct-acting antivirals (DAAs) for HCVGT5-infected patients who have failed NS5A inhibitor-based therapy have not yet been established.

The objective of this study was to evaluate the effectiveness of all-oral DAA-based therapy among HCVGT5-infected patients who had previously failed an NS5A inhibitor-based regimen. The study included 25 HCV-infected patients who had previously failed a regimen containing an NS5A inhibitor. The participants were treated with a combination therapy of sofosbuvir and daclatasvir.

The results showed that 20/25 (80%) of the patients achieved sustained virologic response (SVR)12 at the end of treatment. Four subjects had virologic failure at 8 weeks of treatment, and one subject was lost to follow-up. The study also revealed that there were no significant differences in the SVR12 between genotypes 1 and 5, which suggests that DAAs can achieve satisfactory SVR even in HCVGT5-infected patients who have previously failed NS5A inhibitor-based therapy.

Overall, this study showed that DAA-based therapy is a safe and effective therapy for HCVGT5-infected patients who have failed NS5A inhibitor-based therapy. The results suggest that further research is warranted to further study the efficacy of such regimens.

This study had several limitations. Firstly, the sample size was small and consisted of mostly male patients, which may limit the generalizability of the findings. Secondly, the researchers did not compare the results to other therapeutic regimens, such as interferon or combination therapies. Lastly, the follow-up period was limited to 12 weeks, which may not be sufficient to detect relapse or late relapsers, further research with a longer follow-up period is required.